• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Stage II/III Colorectal Cancer Patients with Mismatch Repair Deficiency Need More Personalized Adjuvant Chemotherapy.

作者信息

Chen Mian, Deng Shenghe, Cao Yinghao, Huang Liang, Cai Kailin

机构信息

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital Sun Yat-sen University, Guangzhou, Guangdong, China.

出版信息

Ann Surg Oncol. 2024 Nov;31(12):7854-7855. doi: 10.1245/s10434-024-15926-1. Epub 2024 Jul 29.

DOI:10.1245/s10434-024-15926-1
PMID:39073663
Abstract
摘要

相似文献

1
ASO Author Reflections: Stage II/III Colorectal Cancer Patients with Mismatch Repair Deficiency Need More Personalized Adjuvant Chemotherapy.ASO作者反思：错配修复缺陷的II/III期结直肠癌患者需要更个性化的辅助化疗。
Ann Surg Oncol. 2024 Nov;31(12):7854-7855. doi: 10.1245/s10434-024-15926-1. Epub 2024 Jul 29.
2
Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms.线粒体DNA拷贝数作为指导错配修复缺陷的II期和III期结直肠癌患者辅助化疗的生物标志物：寻求益处与避免危害
Ann Surg Oncol. 2024 Sep;31(9):6320-6330. doi: 10.1245/s10434-024-15759-y. Epub 2024 Jul 10.
3
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.错配修复状态在结直肠癌中对辅助化疗治疗决策的影响：一项基于澳大利亚人群的多中心研究。
Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.
4
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.II期和III期结直肠癌的微卫星不稳定性、预后及药物敏感性：谜题愈发复杂
J Natl Cancer Inst. 2011 Jun 8;103(11):841-4. doi: 10.1093/jnci/djr170. Epub 2011 May 19.
5
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.用于II期和III期结直肠癌基于FOLFOX辅助治疗的风险分层和反应预测的微小RNA特征。
Mol Cancer. 2023 Jan 20;22(1):13. doi: 10.1186/s12943-022-01699-2.
6
A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.Ⅱ期和Ⅲ期结肠癌中错配修复状态与胸苷酸合成酶表达的联合分析。
Clin Colorectal Cancer. 2013 Jun;12(2):128-35. doi: 10.1016/j.clcc.2012.11.003. Epub 2012 Dec 29.
7
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.基于组合癌症特征的基因签名集的鉴定和构建，以预测 II 期结直肠癌的复发和化疗获益。
JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.
8
Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.III期结直肠癌中扩展RAS突变和错配修复状态的预后及预测价值
Cancer Sci. 2016 Jul;107(7):1006-12. doi: 10.1111/cas.12950. Epub 2016 Jun 28.
9
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.错配修复、KRAS 和 BRAF 突变在预测结直肠癌复发和化疗获益中的价值。
J Clin Oncol. 2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366. Epub 2011 Mar 7.
10
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.错配修复缺陷在结直肠癌个体化管理中的作用
Int J Environ Res Public Health. 2016 Sep 8;13(9):892. doi: 10.3390/ijerph13090892.

本文引用的文献

1
Are Positive Biopsy Margins in Melanoma Significant?: A Cohort Study of Micro- Versus Macroscopic Margin Status and Their Impact on Residual Disease and Survival.黑色素瘤活检切缘阳性是否具有重要意义？：一项关于微观与宏观切缘状态及其对残留疾病和生存影响的队列研究。
Ann Surg Oncol. 2025 Jan;32(1):474-481. doi: 10.1245/s10434-024-16301-w. Epub 2024 Oct 9.
2
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.结肠癌临床实践指南（2021 年第 2 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359. doi: 10.6004/jnccn.2021.0012.
3
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
III 期结肠癌患者接受 FOLFOX 辅助化疗时错配修复缺陷状态的作用：来自 2 项随机临床试验的汇总分析。
JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.
4
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.DNA 错配修复（MMR）状态对奥沙利铂为基础的一线化疗治疗复发性或转移性结直肠癌的影响。
Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1.